Influences of three nucleotide drugs on renal function of patients with chronic hepatitis B and intervention effect of telbivudine on renal function injury caused by adefovir dipivoxil
-
摘要: 目的 比较替比夫定(LdT)、恩替卡韦(ETV)、阿德福韦酯(ADV)单药治疗对慢性乙型肝炎(CHB)患者肾功能的影响,探讨替比夫定对所致肾功能损伤的干预效果。 方法 采用随机数字表法将本院收治的309例CHB患者分为LdT组(n=70)、ETV组(n=94)和ADV组(n=145)。另选取本院同期应用ADV治疗后出现轻度肾功能损伤的69例CHB患者,根据后续治疗方案分为ADV转LdT组(n=33)和ADV转ETV组(n=36)。比较5组患者0、48、96、144周时的血清肌酐(SCr)、肾小球滤过率估值(eGFR)水平; 比较治疗144周时5组患者SCr和eGFR相对基线变化率; 比较治疗144周时5组患者eGFR分布较基线的变化情况。 结果 治疗0、48、96、144周时, ADV转LdT组SCr水平显著下降, eGFR水平显著升高(P<0.05), 而ADV转ETV组SCr、eGFR水平无显著变化。治疗0、48、96、144周时, ADV组、LdT组、ETV组SCr、eGFR水平变化两两比较,差异均有统计学意义(P<0.05)。治疗144周时, LdT组SCr、eGFR相对基线变化率最为显著,特别是在ADV转LdT组中, SCr、eGFR相对基线变化率更为显著。治疗144周时, ADV组、LdT组、ETV组eGFR分布较基线变化显著(P<0.05), 且ADV转ETV组与ADV转LdT组比较有显著差异(P<0.05)。 结论 在应用ADV、LdT、ETV单药治疗CHB患者中, LdT的肾功能保护作用最好, ADV最差, ETV对肾功能无明显影响。对于ADV导致肾功能损伤的患者,应用LdT进行后续治疗可显著改善患者的SCr和eGFR水平,对肾功能有明显的改善作用。Abstract: Objective To compare the effects of single application of telbivudine(LdT), entecavir(ETV)and adefovir dipivoxil(ADV)on renal function of patients with chronic hepatitis B(CHB)and to explore the influence of LdT on renal function injury caused by ADV. Methods Totally 309 CHB patients in our hospital were randomly divided into LdT group(n=70), ETV group(n=94)and ADV group(n=145). In addition, 69 CHB patients with mild renal injury caused by ADV in the same period were divided into ADV transferring to LdT group(n=33)and ADV transferring to ETV group(n=36)according to the follow-up treatment. The serum creatinine(SCr)and estimated GFR(eGFR)level were compared among the 5 groups at the time points of 0, 48, 96 and 144 weeks of treatment. At the time point of 144 weeks, the change rates of SCr and eGFR levels relative to baseline levels were compared among 5 groups. At the time point of 144 weeks, the changes of eGFR distribution against baseline were compared among 5 groups. Results At the time points of 0, - 48, 96, and 144 weeks, the level of SCr in the ADV to LdT group decreased significantly, and the level of eGFR increased significantly(P<0.05), but there was no significant change in the levels of SCr and eGFR in the ADV transferring to ETV group. At the time points of 0, 48, 96, 144 weeks, there were significant differences in levels of SCr and eGFR among ADV group, LdT group and ETV group(P<0.05). At the time point of 144 weeks, the change rates of SCr and eGFR in LdT group was the most significant, especially in the ADV to LdT group. At the time point of 144 weeks, there were significant differences in distribution of eGFR when compared with those of baseline in ADV group, LdT group and ETV group(P<0.05), and there was a significant difference between the ADV transferring to ETV group and the ADV transferring to LdT group(P<0.05). Conclusion Among the CHB patients treated with single application of ADV, LdT and ETV, LdT shows the best protective effect on renal function, ADV is the worst and ETV shows no significant effect on renal function. For patients with renal impairment caused by ADV, application of LdT as a subsequent treatment can significantly improve the levels of SCr and eGFR as well as renal function.
-
-
徐勇, 冯继红. 核苷和核苷酸类药物对慢性乙型肝炎患者肾小球滤过率和血肌酐水平的影响[J]. 临床肝胆病杂志, 2016, 32(2): 279-283. 王宇, 欧晓娟, 马红. 替比夫定对慢性乙型肝炎患者肾功能的影响[J]. 临床和实验医学杂志, 2015(4): 336-339. 陈川英, 涂相林, 程全红, 等. 慢性乙型肝炎患者妊娠早期替比夫定抗病毒的疗效及母婴阻断的临床观察[J]. 中华肝脏病杂志, 2015, 23(1): 9-12. 姜利彬. 替比夫定治疗对慢性乙型肝炎患者肾功能影响的研究[D]. 武汉: 华中科技大学, 2014. 盛丽萍. 替比夫定、恩替卡韦对阿德福韦酯治疗慢性乙型肝炎引起肾功能损害的替代研究[D]. 南宁: 广西医科大学, 2016. 赵康路, 郭秋芳, 叶卫江. 替比夫定与阿德福韦酯联用对慢性乙型肝炎患者肾功能的影响[J]. 药物不良反应杂志, 2015, 17(6): 403-407. 刘宇, 杜漫, 王慧雯, 等. 替比夫定与恩替卡韦对阿德福韦酯相关肾损害的慢性乙型肝炎患者肾功能改善效果比较及其影响因素[J]. 广西医学, 2017, 39(4): 440-443. 陈玉兰, 刘洁, 陈立宇. 三种核苷类似物对慢性乙型肝炎患者肾功能影响的长期随访研究[J]. 解放军医药杂志, 2016, 28(6): 83-86. Lin Y S, Shih S C, Wang H Y, et al. Comparison of telbivudine and entecavir on the change of off-treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients[J]. BMC Gastroenterol, 2017, 17(1): 22-31.
Xun L, Cheng W, Hua T, et al. Assessing glomerular filtration rate(GFR)in elderly Chinese patients with chronic kidney disease(CKD): a comparison of various predictive equations[J]. Arch Gerontol Geriatr, 2010, 51(1): 13-20.
陈雅萍, 张勤俭, 田楠楠, 等. 替比夫定联合阿德福韦酯抗乙肝病毒的疗效分析[J]. 现代消化及介入诊疗, 2015, 20(4): 354-355. 吴刚, 盛云建, 陈文. 阿德福韦酯对慢性乙肝患者Th1/Th2类细胞因子、肝功能及HBV DNA复制的影响[J]. 中国老年学杂志, 2013, 33(21): 5320-5321. 毛惠国. 替比夫定联合阿德福韦酯与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效比较[J]. 中国微生态学杂志, 2012, 24(9): 829-831. Kao J H, Asselah T, Dou X G, et al. Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model[J]. J Gastroenterol Hepatol, 2017, 32(1): 73-81.
Zoulim F, Biakowska-Warzecha J, Diculescu M M, et al. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure[J]. Hepatol Int, 2016, 10(5): 779-788.
Kader C, Sunbul M, Das Y K, et al. Telbivudine attenuates gentamicin-induced kidney injury in rats[J]. Int J Antimicrob Agents, 2017, 49(5): 595-602.
彭梅娟, 王伟, 杨晓飞, 等. 聚乙二醇干扰素α-2a与替比夫定对慢性乙型肝炎患者肾功能影响的比较[J]. 临床肝胆病杂志, 2016, 32(4): 682-686. Gane E J, Deray G, Liaw Y F, et al. Telbivudine improves renal function in patients with chronic hepatitis B[J]. Gastroenterology, 2014, 146(1): 138-146.
Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B[J]. J Hepatol, 2011, 55(6): 1235-1240.
李小溪, 钟春秀, 杨淑玲, 等. 阿德福韦酯和替比夫定单药治疗慢性乙型肝炎对肾脏功能影响的比较[J]. 南方医科大学学报, 2012, 32(6): 826-829. -
期刊类型引用(5)
1. 冯学辉，田龙，胡逸民. 立体定向放射外科治疗脑转移瘤患者颅内出血相关风险因素分析. 国际神经病学神经外科学杂志. 2023(06): 34-39 . 
百度学术
2. 姜晓颖，张晓磊，翟瑞杰，赵晓燕，任文娟. 维持性血液透析患者脑出血的发生与血脂、血压及营养状态等因素的相关性分析. 系统医学. 2022(14): 1-4 . 百度学术
3. 林雪云，石一杰，祝轩，朱会英，邓良彬. 脑微出血与高血压性脑出血转归的关系的纵向研究. 智慧健康. 2021(13): 52-54 . 百度学术
4. 张荣，杨鑫泉，熊婷，唐姗，艾可青，钟红艳，毛永清，王大新. GKT137831降低活性氧自由基水平来缓解阿托伐他汀所致的骨骼肌糖摄取下降. 实用临床医药杂志. 2019(10): 53-57 . 本站查看
5. 黄荣. 他汀类药物治疗脑出血合并高脂血症的效果观察. 基层医学论坛. 2019(29): 4181-4183 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 375
- HTML全文浏览量: 70
- PDF下载量: 9
- 被引次数: 5
下载:
苏公网安备 32100302010246号
